Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).

MLA

Yang, Yunpeng, et al. “Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (Oncology PRogram by InnovENT Anti-PD-1-11).” Journal of Thoracic Oncology, vol. 15, no. 10, Oct. 2020, pp. 1636–46. EBSCOhost, https://doi.org/10.1016/j.jtho.2020.07.014.

APA

Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Ma, R., Bi, M., Ren, X., Zhou, J., Li, B., Song, Y., Feng, J., Li, J., He, Z., Zhou, R., & Li, W. (2020). Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). Journal of Thoracic Oncology, 15(10), 1636–1646. https://doi.org/10.1016/j.jtho.2020.07.014

Chicago

Yang, Yunpeng, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, et al. 2020. “Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (Oncology PRogram by InnovENT Anti-PD-1-11).” Journal of Thoracic Oncology 15 (10): 1636–46. doi:10.1016/j.jtho.2020.07.014.